Wockhardt’s Main Drug Factory Faces FDA Ban After Lapses
This article is for subscribers only.
Wockhardt Ltd. was banned from selling some medicines to the U.S. from a second factory in India after regulators added it to a list of restricted facilities. The stock slumped as much as 14 percent.
Wockhardt’s Chikalthana plant in Aurangabad, its biggest by revenue, was added to the U.S. Food and Drug Administration’s “red list,” which means the Mumbai-based company’s products may be detained without physical examination, the FDA said in a statement yesterday.